FDA Approves Noctiva Nasal Spray for Nocturnal Polyuria

Share this content:
FDA Approves Noctiva Nasal Spray for Nocturnal Polyuria
FDA Approves Noctiva Nasal Spray for Nocturnal Polyuria

MONDAY, March 6, 2017 (HealthDay News) -- Noctiva (desmopressin acetate) nasal spray has been approved by the U.S. Food and Drug Administration to treat frequent urination at night due to nocturnal polyuria.

Noctiva is the first drug approved to treat nocturnal polyuria in the United States, the FDA added. Noctiva, taken about 30 minutes before bed, is designed to increase absorption of water through the kidneys, decreasing urine production. Before prescribing Noctiva, health care providers should confirm overproduction of urine at night by collecting a 24-hour urine sample, the FDA recommended. They should also make sure a patient's habits, such as excessive consumption of fluids, may not be contributing to the problem.

The drug's effectiveness was evaluated in two, 12-week clinical trials involving 1,045 patients aged 50 and older with nocturnal polyuria. The drug's label warns of an elevated risk for hyponatremia, which if severe could be life threatening if not promptly treated, the FDA said.

Noctiva should not be used by patients with symptomatic congestive heart failure or uncontrolled hypertension, the FDA added. It should also not be used by pregnant women or children. The drug's most common side effects include nasal discomfort, nasal congestion, sneezing, an increase in blood pressure, back pain, nose bleed, bronchitis, and dizziness.

Noctiva is marketed by Milford, Pa.- based Renaissance Lakewood for Serenity Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »